All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Sirexatamab Plus Bevacizumab/Chemo Improves Outcomes in DKK1-High mCRC

October 19th 2025

Sirexatamab plus bevacizumab shows promise in improving survival for patients with DKK1-high metastatic colorectal cancer.

First-Line Disitamab Vedotin Plus Toripalimab Yields Survival Advantage in HER2+ Advanced Urothelial Cancer

October 19th 2025

Frontline disitamab vedotin plus toripalimab significantly improved PFS and OS in HER2-expressing locally advanced or metastatic urothelial carcinoma.

Second-Line Sacituzumab Tirumotecan Displays PFS Benefit in EGFR+ NSCLC

October 19th 2025

Sacituzumab tirumotecan reduced the risk of progression or death by 51% in nonsquamous EGFR-mutated NSCLC resistant to EGFR TKIs.

Tislelizumab Plus Chemo/Concurrent Chemoradiotherapy Yields Survival Advantage in Locally Advanced ESCC

October 19th 2025

Tislelizumab plus induction chemotherapy and concurrent chemoradiation demonstrated efficacy worthy of further study in locally advanced ESCC.

Zipalertinib Shows Early Efficacy With Manageable Safety in EGFR-Mutant NSCLC With CNS or Leptomeningeal Disease

October 19th 2025

Zipalertinib demonstrated preliminary efficacy and low rates of treatment-related dose reductions and discontinuations in NSCLC harboring EGFR mutations and CNS metastases and/or leptomeningeal disease.

Enfortumab Vedotin Plus Pembrolizumab Shows First-Line Activity in PD-L1+ Recurrent/Metastatic HNSCC

October 19th 2025

Enfortumab vedotin plus pembrolizumab demonstrated meaningful first-line clinical activity in PD-L1–positive recurrent or metastatic HNSCC.

Durvalumab Plus Chemo Yields Inconclusive Results in Advanced Pleural Mesothelioma

October 19th 2025

Durvalumab in combination with chemotherapy produced outcomes consistent with prior studies in patients with advanced pleural mesothelioma.

Chemotherapy Plus Durvalumab, Bevacizumab, and Olaparib Fails to Offer OS Benefit in Newly Diagnosed Non-tBRCA–Mutated Ovarian Cancer

October 19th 2025

Chemotherapy plus durvalumab, bevacizumab, and olaparib did not significantly prolong OS in non-tBRCA-mutated ovarian cancer.

Atezolizumab Plus Chemotherapy Demonstrates Noninferior Survival Vs Chemotherapy Alone in Advanced/Recurrent Endometrial Cancer

October 19th 2025

The addition of atezolizumab to chemotherapy demonstrated noninferior survival vs chemotherapy alone in advanced or recurrent endometrial cancer.

Enzalutamide Plus Leuprolide Yields OS Benefit in High-Risk, Biochemically Recurrent Prostate Cancer

October 19th 2025

Enzalutamide plus leuprolide acetate led to a 40.3% lower risk of death vs leuprolide acetate alone in high-risk, biochemically recurrent prostate cancer.

Relacorilant Plus Nab-Paclitaxel Yields PFS Advantage in PARP Inhibitor–Exposed PROC

October 19th 2025

The addition of relacorilant to nab-paclitaxel produced a PFS benefit vs nab-paclitaxel alone in PROC with a history of PARP inhibitor exposure.

Sacituzumab Govitecan Reduces Risk of Progression or Death by 38% in PD-1/PD-L1–Ineligible TNBC

October 19th 2025

Sacituzumab govitecan reduced the risk for disease progression or death by 38% vs chemotherapy in previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer.

Capivasertib Plus Abiraterone Acetate, Prednisone, and ADT Extends rPFS in PTEN-Deficient HSPC

October 19th 2025

Capivasertib plus abiraterone acetate, prednisone, and androgen deprivation therapy was active in PTEN-deficient de novo metastatic HSPC.

TUB-040 Yields Responses Across Dose Levels in Platinum-Resistant High-Grade Serous Ovarian Cancer

October 19th 2025

NAPISTAR1-01 showed enduring benefit with TUB-040 in patients with platinum-resistant high-grade serous ovarian cancer.

Infinatamab Deruxtecan Shows Encouraging CNS Activity in Extensive-Stage Small Cell Lung Cancer

October 19th 2025

I-DXd showed intracranial efficacy and manageable safety in ES-SCLC with brain metastases, per data from the IDeate-Lung01 study.

Pembrolizumab/Lenvatinib Combo Is Active, Safe in Uveal Melanoma

October 19th 2025

Pembrolizumab plus lenvatinib was safe and active in HLA-A*02:01–negative and –positive uveal melanoma.

Gedatolisib Plus Fulvestrant ± Palbociclib Drives PFS Improvement in PIK3CA Wild-Type, HR+/HER2– Advanced Breast Cancer

October 19th 2025

Gedatolisib plus fulvestrant, with or without palbociclib, improved PFS in pretreated, HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.

Sac-TMT Yields PFS Benefit Over Chemotherapy in Pretreated HR+, HER2– Metastatic Breast Cancer

October 19th 2025

Sac-TMT bested chemotherapy in terms of PFS in previously treated HR+, HER2– metastatic breast cancer.

Perioperative Enfortumab Vedotin Plus Pembrolizumab May Represent New SOC in Cisplatin-Ineligible MIBC

October 18th 2025

Enfortumab vedotin plus pembrolizumab significantly improved survival and pCR vs surgery alone in cisplatin-ineligible MIBC per KEYNOTE-905 data.

Neoadjuvant T-DXd Plus THP Yields pCR Benefit in High-Risk, HER2+ Early-Stage Breast Cancer

October 18th 2025

Neoadjuvant T-DXd followed by THP improved pathological complete response rate in high-risk, HER2-positive early-stage breast cancer.